Showing results (1571-1580 of 1,899) with videos related to
Sort By:
Pageof 190
Immunotherapy|April 30, 2020
Endocrine adverse events related with immune checkpoint inhibitors: an update for cliniciansMaria V Deligiorgi, Mihalis I Panayiotidis, Dimitrios T TrafalisImmunotherapy|April 16, 2020
Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?Joseph Kattan, Clarisse Kattan, Tarek AssiImmunotherapy|February 18, 2010
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapyBurles A Johnson, Babak Baban, Andrew L MellorImmunotherapy|February 23, 2010
Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodesNancy I Kerkvliet, Linda B Steppan, William Vorachek, et al.Immunotherapy|August 4, 2018
Cytokine-induced killer cell therapy as a promising adjunctive immunotherapy for multidrug-resistant pulmonary TB: a case reportPing Xu, Yu Pang, Junchi Xu, et al.Immunotherapy|August 4, 2018
Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumabRenuka Sivendran, José Ramírez, Monica Ramchandani, et al.Immunotherapy|June 10, 2017
Cellular immunotherapy of cancer: an overview and future directionsZiqi Tao, Shuang Li, Thomas E Ichim, et al.Immunotherapy|April 11, 2018
Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safetyPeter Socrates Creticos, Oliver PfaarImmunotherapy|May 17, 2018
IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgGMelvin Berger, Thomas Harbo, David R Cornblath, et al.Immunotherapy|July 17, 2018
Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumabMelissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, et al.Pageof 190